Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab, KRAS Vaccine, and Nivolumab in PDAC and Refractory NSCLC
NCT06015724Phase 2Active, not recruiting
- Sponsor
- Georgetown University
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, v941, nivolumab in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), sponsored by Georgetown University. Started Jan 2024; status: active, not recruiting.
02
Drugs
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06015724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015724.